Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RemeGen Granted US Fast Track for Dual-Target Candidate in Sjögren's Syndrome

publication date: Apr 4, 2024

Yantal’s RemeGen was granted Fast Track Designation in the US for its novel BLyS/APRIL dual-target fusion protein candidate for primary Sjögren's syndrome (pSS). The candidate, telitacicept, is designed to inhibit the overexpression of two cytokines, B-cell lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). RemeGen says the two-pronged approach prevents abnormal differentiation and maturation of B-cells, treating various autoimmune diseases mediated by B-cells. A Phase III clinical trial for this indication is currently underway in China. Telitacicept was approved to start US trials in late 2023. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital